Europe’s Bio Revolution: Biological innovations for complex problems

Europe—and the world—faces major challenges, from health threats to climate risk. Advances in biological science can be part of the solution, but Europe needs new impetus to translate its strong science base into a broader application of biological solutions to these complex and difficult issues. One way to breathe newContinue Reading

Addressing BC’s Growing Bio Health Sector: Life Sciences BC Connects Skilled Talent for BC Life Sciences Success

VANCOUVER, British Columbia–(BUSINESS WIRE)–A skilled talent gap is looming. Life Sciences BC is supporting and accelerating the growth of BC’s growing life sciences sector through connecting skilled talent with new opportunities through the third annual Career Connect Day presented by BioTalent Canada, taking place virtually on Friday, January 21, 2022.Continue Reading

Massive Bio Hires Steve McNamara as Chief Operating Officer to Scale Global AI-Enabled Access to Cancer Clinical Trials and Further Maintain Record Growth

NEW YORK–(BUSINESS WIRE)–Massive Bio, Inc., the leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology, announced the hiring of Steve McNamara as chief operating officer. McNamara is a veteran strategic business technology leader who brings deep experience delivering data-driven operational excellence using predictive analytics atContinue Reading

Industry collab: Oregon Bio and Onward Eugene announce development partnership to grow jobs and biotech in the Willamette Valley

EUGENE, Ore.–(BUSINESS WIRE)–More than 100 biotech and life science companies, labs and startups in Lane County – and those yet to be – are sharing in today’s exciting announcement that the Oregon Bioscience Association and Onward Eugene are formally partnering to accelerate the growth of the bioscience industry in theContinue Reading

GreenLight Biosciences Announces Business Agreement With Environmental Impact Acquisition Corp. to Become Publicly Traded Company, Allowing It to Better Harness Its Breakthrough Platform to Develop and Produce RNA for Human Therapies and Agriculture | DNA RNA and Cells

IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies Details Category: More News Published on Tuesday, 05 October 2021 18:54 Hits: 143 Participating Investors include Viva BioInnovator, Eli Lilly and Company, Opaleye Management, Orange Grove Bio and Alexandria Venture Investments Foundational ScienceContinue Reading